J&J backs financing round for Stanford CAR-T cell therapy spinout Link Cellnews2025-12-16T16:03:20+00:00December 16th, 2025|Endpoints News|
Kyverna to take autoimmune CAR-T to FDA after success in stiff person syndrome trialnews2025-12-15T16:10:23+00:00December 15th, 2025|Endpoints News|
Western genetic medicine makers turn to Chinese investigator-initiated trialsnews2025-12-15T12:30:18+00:00December 15th, 2025|Endpoints News|
Tenaya targets $60M offering after heart disease pipeline updatesnews2025-12-12T12:04:38+00:00December 12th, 2025|Endpoints News|
In a first, FDA approves a gene therapy from a nonprofitnews2025-12-10T16:02:33+00:00December 10th, 2025|Endpoints News|
#ASH25: Early in vivo CAR-T results like Kelonia’s elicit excitement across the fieldnews2025-12-09T16:04:26+00:00December 9th, 2025|Endpoints News|
EpilepsyGTx gets $33M to test epilepsy gene therapy in Phase 1/2anews2025-12-09T16:00:08+00:00December 9th, 2025|Endpoints News|
Cell and gene therapy benefits company Aradigm raises $20Mnews2025-12-09T12:00:26+00:00December 9th, 2025|Endpoints News|
FDA sets new, higher bar for CAR-T cancer treatments to prove superioritynews2025-12-08T19:57:56+00:00December 8th, 2025|Endpoints News|
#ASH25: AstraZeneca’s dual-targeting CAR-T sees similar responses in Western patients as in Chinanews2025-12-06T20:00:15+00:00December 6th, 2025|Endpoints News|
